Method Validation for Diagnostic Assays

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Diagnostic assay validation requires aligning analytical performance studies with FDA laboratory developed test (LDT) expectations, CLSI protocol standards, and ISO 15189 quality management requirements.
• Start by defining the assay's intended use and clinical claim, then select validation parameters and acceptance criteria that match the claimed performance.
• Validation is a continuous process, any modification to a validated method requires re-evaluation of specific performance characteristics based on the nature and scope of the change.

Understanding the Regulatory Landscape for Diagnostic Assay Validation

Developers of in-house diagnostic tests face a complex environment where multiple standards and guidance documents overlap and sometimes conflict. The primary frameworks governing diagnostic assay validation in the United States include FDA regulations for laboratory developed tests, CLSI guidelines for method evaluation, and ISO 15189 for medical laboratory quality competence. Each framework addresses validation from a different perspective, and understanding how they interrelate is essential for regulatory acceptance.

The FDA has historically exercised enforcement discretion over LDTs, but recent regulatory shifts have signaled increased oversight. Laboratories developing in-house assays must demonstrate that their validation practices meet analytical performance standards comparable to FDA cleared or approved tests. The CLSI provides detailed protocol documents, such as EP05 for precision evaluation and EP17 for detection capability, which serve as the technical backbone for validation studies. ISO 15189, while primarily a quality management standard for medical laboratories, incorporates validation requirements that emphasize fit for purpose and ongoing verification of assay performance.

The practical challenge for assay developers is that these frameworks do not always align perfectly. FDA expectations focus on analytical and clinical validity for regulatory decision making, CLSI protocols emphasize statistical rigor and experimental design, and ISO 15189 integrates validation into a broader quality management system. A validation strategy that satisfies one framework may not automatically satisfy the others, requiring developers to map their validation activities across all applicable requirements.

The CLSI H62 guideline for flow cytometry assay validation, released in 2021, provides a useful example of how modern validation frameworks address platform specific considerations. This guideline covers platform workflow, quality system essentials, instrument setup and standardization, assay development and optimization, and fit for purpose analytical method validation. It also addresses validation strategies after a validated method has been modified, which is a common scenario in clinical laboratories that adapt published methods to their specific platforms and patient populations.

Core Validation Parameters and Their Definitions

Analytical Sensitivity and Limit of Detection

Analytical sensitivity refers to the ability of an assay to detect small quantities of the target analyte. This parameter is typically expressed as the limit of detection, which represents the lowest concentration or amount of analyte that can be reliably distinguished from a blank sample. The limit of detection is not a fixed property of an assay but depends on the matrix being tested, the instrument platform, and the statistical method used to define it.

For diagnostic assays, the limit of detection must be established using clinically relevant matrices instead of idealized buffer solutions. A molecular diagnostic test for a pathogen, for example, should have its limit of detection established in the specimen type that will be tested clinically, such as plasma, serum, or respiratory specimens. Matrix effects can substantially impact assay performance, and validation studies that use only purified analyte in buffer may overestimate the assay's true detection capability.

The limit of blank is a related parameter that must be established before determining the limit of detection. The limit of blank represents the highest apparent analyte concentration expected when replicates of a blank sample are measured. It is determined by measuring a blank sample multiple times and calculating the mean plus a statistical multiple of the standard deviation. The limit of detection is then typically set at a concentration that produces a signal reliably above the limit of blank.

Analytical Specificity and Interference

Analytical specificity describes the ability of an assay to measure only the intended analyte without cross reacting with other substances present in the sample. For molecular assays, specificity concerns include cross reactivity with closely related organisms or genetic variants, while for immunoassays, specificity concerns include cross reactivity with structurally similar molecules and interference from heterophilic antibodies.

Interference testing is a critical component of specificity evaluation. Common interfering substances include hemoglobin, bilirubin, lipids, and therapeutic drugs that may be present in patient samples. Endogenous substances such as rheumatoid factor and human anti mouse antibodies can also interfere with immunoassay performance. The validation plan should identify potential interferents based on the assay chemistry and the patient population being tested, then evaluate each at clinically relevant concentrations.

Cross reactivity studies for infectious disease assays should include a panel of organisms that are phylogenetically related to the target or that may be present in the same clinical specimen. The selection of cross reactivity panel members should be justified based on the assay's intended use and the differential diagnosis considerations for the target condition.

Precision and Reproducibility

Precision refers to the closeness of agreement between independent measurement results obtained under stipulated conditions. It is typically expressed as the coefficient of variation and is evaluated at multiple levels: repeatability within a single run, intermediate precision across runs and days, and reproducibility across different laboratories or operators.

CLSI EP05 provides a standardized protocol for precision evaluation that involves testing multiple samples across multiple runs and days. The protocol specifies the number of replicates, the number of runs, and the statistical analysis methods for estimating within run, between run, and between day components of variance. Precision studies should include samples spanning the assay's measuring range, with particular attention to concentrations near the clinical decision point.

The acceptance criteria for precision should be based on the assay's intended use and the clinical consequences of measurement variability. A quantitative assay used to monitor disease progression may require tighter precision than a qualitative screening assay. The validation plan should specify precision acceptance criteria before the study begins, and the statistical analysis should include confidence intervals around the precision estimates.

Accuracy and Trueness

Accuracy describes the closeness of agreement between the measured value and the true value of the analyte. Trueness refers to the closeness of agreement between the average of an infinite number of replicate measurements and the true value. Accuracy is typically evaluated through comparison with a reference method, analysis of certified reference materials, or recovery studies using spiked samples.

Method comparison studies should include samples spanning the clinically relevant range, with particular attention to concentrations near medical decision points. The comparison method should be well characterized and traceable to a higher order standard when available. The statistical analysis should include regression analysis, bias estimation, and evaluation of differences across the measuring range.

For assays where no reference method or certified reference material exists, alternative approaches may be necessary. These include comparison with a predicate method that has established clinical utility, analysis of proficiency testing samples with known values, or correlation with clinical outcomes. The validation report should clearly describe the accuracy assessment approach and its limitations.

CLSI EP05 and Precision Evaluation Protocols

CLSI EP05 is the foundational document for precision evaluation of quantitative measurement procedures. The protocol provides a standardized experimental design that separates within run, between run, and between day components of variance. The typical design involves testing two or more samples with two replicates per run, two runs per day, over a minimum of twenty days.

The statistical analysis in EP05 uses analysis of variance to estimate variance components. The within run variance captures the random error associated with replicate measurements in a single run. The between run variance captures additional variability associated with different runs, such as reagent lot changes, calibration events, and environmental fluctuations. The between day variance captures longer term variability associated with different days of operation.

The EP05 protocol also provides guidance on outlier detection and handling. Outliers can substantially inflate variance estimates, and the protocol specifies statistical tests for identifying outliers and procedures for investigating their cause. Outliers should not be removed simply to improve precision estimates, each outlier should be investigated to determine whether it represents a correctable procedural error or an inherent property of the assay.

For qualitative assays, precision evaluation focuses on the reproducibility of positive and negative results and the consistency of signal near the cutoff. The precision of qualitative assays is often evaluated using replicate testing of samples near the assay cutoff, where the risk of discordant results is highest. The proportion of concordant results across replicates provides a measure of assay robustness.

ISO 15189 Requirements for Validation and Verification

ISO 15189 specifies requirements for quality and competence in medical laboratories. The standard distinguishes between validation, which is required for laboratory developed tests and modified methods, and verification, which is required for methods that have been previously validated by the manufacturer. This distinction is important for assay developers because it determines the scope of the performance evaluation required.

Validation under ISO 15189 requires the laboratory to confirm that the method is fit for its intended purpose. This includes evaluation of analytical performance characteristics such as measurement accuracy, measurement precision, analytical sensitivity, analytical specificity, measuring interval, and reference intervals. The validation should also address clinically relevant performance characteristics, including diagnostic sensitivity and specificity when appropriate.

Verification under ISO 15189 requires the laboratory to confirm that it can achieve the performance specifications claimed by the manufacturer. This typically involves a more limited evaluation, focusing on accuracy and precision, with the expectation that the laboratory's performance is comparable to the manufacturer's claims. Verification studies should be designed based on the manufacturer's instructions and the laboratory's specific conditions.

The ISO 15189 framework also requires ongoing monitoring of assay performance after initial validation or verification. This includes participation in external quality assessment programs, internal quality control procedures, and periodic review of assay performance data. Any significant change in assay performance should trigger investigation and, if necessary, revalidation of the affected parameters.

FDA Expectations for Laboratory Developed Tests

The FDA has articulated specific expectations for the analytical validation of laboratory developed tests. These expectations are detailed in the FDA's guidance documents and are designed to ensure that LDTs meet the same analytical performance standards as FDA cleared or approved tests. The FDA expects validation studies to be designed based on the assay's intended use, with acceptance criteria that are scientifically justified and clinically meaningful.

For analytical sensitivity, the FDA expects the limit of detection to be established using clinically relevant matrices and to include sufficient replicates to provide statistical confidence. The FDA also expects the limit of blank to be established and reported, and the relationship between the limit of blank and limit of detection to be clearly described.

For analytical specificity, the FDA expects interference studies to include potentially interfering substances at clinically relevant concentrations. Cross reactivity studies should include a panel of organisms or substances that are likely to be encountered in the intended patient population. The selection of interference and cross reactivity panel members should be justified in the validation report.

For precision, the FDA expects studies to include multiple runs, multiple days, multiple operators, and multiple reagent lots when feasible. The precision study design should reflect the conditions of routine clinical use, and the acceptance criteria should be based on the assay's intended use and the clinical consequences of variability.

The FDA also expects validation of the assay's measuring interval, including the lower limit of quantification and upper limit of quantification. The measuring interval should be established using samples with known analyte concentrations, and the linearity of the assay across the measuring interval should be demonstrated.

Fit for Purpose Validation and Risk Based Approaches

The concept of fit for purpose validation recognizes that the extent and rigor of validation should be proportional to the assay's intended use and the clinical consequences of incorrect results. A screening assay used to rule out disease may require different validation emphasis than a confirmatory assay used to guide treatment decisions. Similarly, an assay used for monitoring chronic disease may require different precision and accuracy standards than an assay used for initial diagnosis.

The CLSI H62 guideline for flow cytometry assays explicitly adopts a fit for purpose approach to analytical method validation. This approach requires the laboratory to define the assay's intended use, identify the performance characteristics that are critical for that intended use, and design validation studies that address those critical characteristics. The fit for purpose approach also recognizes that not every validation parameter is equally important for every assay.

Risk based validation extends the fit for purpose concept by formally assessing the risks associated with assay failure. This includes considering the probability of assay failure, the consequences of incorrect results, and the effectiveness of mitigation strategies. Risk assessment should be documented and should inform the design of validation studies, the stringency of acceptance criteria, and the ongoing quality control strategy.

The fit for purpose approach also applies to revalidation after assay modifications. The CLSI H62 guideline provides recommendations for which validation parameters to evaluate depending on the type of modification. Minor modifications, such as changing a reagent lot from the same manufacturer, may require only limited verification of performance. Major modifications, such as changing the detection chemistry or the specimen type, may require full revalidation of multiple parameters.

Method Modification and Revalidation Strategies

Laboratories frequently modify published or manufacturer validated methods to adapt them to their specific platforms, patient populations, or operational needs. Each modification has the potential to affect assay performance, and the validation strategy must be proportional to the risk associated with the modification.

The CLSI H62 guideline provides a framework for determining which validation parameters to evaluate after a method modification. The key consideration is whether the modification affects the assay's analytical principle, the specimen type, the measuring range, or the clinical interpretation. Modifications that affect these fundamental aspects of the assay require more extensive revalidation than modifications that affect only operational details.

Common method modifications include changes to specimen collection or processing procedures, changes to reagent formulations or sources, changes to instrument platforms or settings, and changes to data analysis algorithms. Each type of modification has different implications for assay performance. A change in specimen processing, for example, may affect recovery, precision, and the limit of detection. A change in data analysis algorithm may affect the interpretation of results without affecting the analytical measurement itself.

The revalidation plan should specify the parameters to be evaluated, the number of samples and replicates, and the acceptance criteria for each parameter. The plan should also specify the conditions under which the modified method can be implemented, such as successful completion of all revalidation studies and review of the validation data by qualified personnel.

Designing a Validation Study Protocol

Defining the Intended Use and Performance Claims

The validation study protocol begins with a clear statement of the assay's intended use. This statement should describe the analyte being measured, the specimen type, the patient population, and the clinical application. The intended use statement drives all subsequent validation decisions, including the selection of validation parameters, the design of experiments, and the acceptance criteria.

The performance claims should be specific and measurable. Instead of stating that the assay is sensitive, the validation protocol should state the claimed limit of detection in the intended specimen type. Instead of stating that the assay is precise, the protocol should state the claimed coefficient of variation at specified analyte concentrations. Specific performance claims enable objective evaluation of validation data and provide a basis for ongoing monitoring of assay performance.

The intended use statement should also address the clinical context of the assay. This includes the prevalence of the target condition in the intended population, the consequences of false positive and false negative results, and the role of the assay in the clinical decision pathway. This clinical context informs the stringency of acceptance criteria and the relative emphasis on different validation parameters.

Selecting Samples and Establishing Acceptance Criteria

The selection of samples for validation studies should reflect the intended use of the assay. Samples should include the full range of analyte concentrations expected in clinical use, with particular attention to concentrations near clinical decision points. Samples should be in the intended specimen type and should include the range of matrix conditions expected in clinical samples.

For assays where characterized samples are not available, the validation plan should describe the approach for creating or obtaining suitable samples. This may include spiking analyte into negative matrix, diluting high concentration patient samples, or obtaining samples from external sources. The validation plan should also address the stability of validation samples and the conditions for their storage and handling.

Acceptance criteria should be established before the validation study begins and should be based on the assay's intended use and performance claims. The acceptance criteria should be specific, measurable, and clinically meaningful. For precision, the acceptance criteria should specify the maximum allowable coefficient of variation at each concentration level. For accuracy, the acceptance criteria should specify the maximum allowable bias or the allowable difference from the reference method.

Executing the Validation Study and Documenting Results

The validation study should be executed according to the approved protocol, with careful attention to the conditions specified in the protocol. This includes the number of runs, the number of replicates, the order of testing, and the handling of samples. Any deviations from the protocol should be documented and investigated.

The validation data should be analyzed using appropriate statistical methods, and the results should be compared to the pre specified acceptance criteria. The validation report should include the raw data, the statistical analysis, the comparison to acceptance criteria, and the conclusions about assay performance. The report should also include any limitations of the validation study and recommendations for ongoing monitoring.

The validation report should be reviewed and approved by qualified personnel before the assay is implemented for clinical use. The review should confirm that the validation study was executed according to the protocol, that the data analysis was appropriate, and that the assay meets the pre specified acceptance criteria. The review should also consider whether any additional validation studies are needed to address gaps or limitations in the initial validation.

At a Glance

Comparison of Regulatory Frameworks for Assay Validation

Practical Implementation Steps for Assay Validation

Step 1: Establish the Validation Team and Governance Structure

Assay validation requires input from multiple disciplines, including laboratory science, biostatistics, clinical medicine, and quality management. The validation team should include individuals with expertise in each of these areas, and the team should have clear authority and responsibility for the validation process. The governance structure should define how validation decisions are made, how conflicts are resolved, and how the validation report is reviewed and approved.

The validation team should begin by reviewing the applicable regulatory requirements and professional standards. This review should identify the specific validation expectations from FDA, CLSI, and ISO 15189 that apply to the assay being developed. The team should also review the scientific literature for similar assays to understand the performance characteristics that are achievable and the validation approaches that have been used.

Step 2: Conduct a Risk Assessment and Gap Analysis

The risk assessment should identify the potential sources of assay failure and the consequences of incorrect results. This assessment should consider the assay chemistry, the specimen type, the instrument platform, the operator skill requirements, and the clinical application. The risk assessment should be documented and should inform the design of the validation study.

The gap analysis should compare the current state of assay development to the requirements for clinical implementation. This analysis should identify the validation studies that are needed, the resources required to conduct those studies, and the timeline for completion. The gap analysis should also identify any technical or operational issues that need to be resolved before validation can begin.

Step 3: Develop the Validation Master Plan

The validation master plan should describe the overall approach to validation, including the validation parameters to be evaluated, the study designs, the sample requirements, the acceptance criteria, and the timeline. The plan should also describe the documentation requirements, the data management approach, and the review and approval process.

The validation master plan should be reviewed and approved by the validation team and by appropriate institutional oversight. The plan should be updated as the validation proceeds, with any changes documented and justified. The final validation report should reference the validation master plan and describe any deviations from the plan.

Step 4: Execute Validation Studies and Manage Data

The validation studies should be executed according to the approved protocols, with careful attention to the conditions specified in the protocols. The data should be recorded in a manner that is complete, accurate, and traceable. The data management approach should include procedures for data review, outlier investigation, and statistical analysis.

The validation team should meet regularly to review progress, address issues, and make decisions about the validation process. Any issues that arise during validation should be documented and investigated, and the investigation should be documented in the validation report.

Step 5: Analyze Data and Prepare the Validation Report

The data analysis should be conducted using appropriate statistical methods, and the results should be compared to the pre specified acceptance criteria. The validation report should include the raw data, the statistical analysis, the comparison to acceptance criteria, and the conclusions about assay performance.

The validation report should also include a discussion of the limitations of the validation study and the implications of those limitations for clinical use. The report should make specific recommendations about the conditions under which the assay can be implemented, the quality control procedures that should be used, and the ongoing monitoring that is required.

Step 6: Review, Approve, and Implement the Validated Assay

The validation report should be reviewed by qualified personnel who were not directly involved in the validation studies. The review should confirm that the validation was conducted according to the approved plan, that the data analysis was appropriate, and that the assay meets the pre specified acceptance criteria.

After approval, the assay can be implemented for clinical use. The implementation should include training of laboratory personnel, establishment of quality control procedures, and communication of the assay's performance characteristics to clinical users. The implementation should also include a plan for ongoing monitoring of assay performance and for revalidation if the assay is modified.

Records and Measurements for Validation Documentation

Essential Documentation Components

The validation documentation should provide a complete and traceable record of the validation process. This includes the validation master plan, the individual study protocols, the raw data, the statistical analysis, the validation report, and the approval documentation. Each document should be version controlled, and the relationships between documents should be clearly described.

The validation master plan should describe the overall approach to validation and should be approved before validation studies begin. The individual study protocols should describe the specific experiments to be conducted, including the samples, replicates, runs, and statistical analysis methods. The raw data should be recorded in a manner that is complete and traceable, with any corrections documented and explained.

The validation report should synthesize the results of all validation studies and should state the conclusions about assay performance. The report should include the pre specified acceptance criteria, the observed results, and the comparison between the two. The report should also include any limitations of the validation and recommendations for ongoing monitoring.

Data Integrity and Traceability Requirements

Data integrity is a fundamental requirement for validation documentation. The data should be attributable, legible, contemporaneous, original, and accurate. The data should be recorded at the time the measurement is made, and any corrections should be made in a manner that preserves the original entry.

The traceability of validation data includes the ability to trace each measurement to the instrument, reagent lot, operator, and sample that produced it. This traceability is essential for investigating unexpected results and for demonstrating the validity of the validation data. The laboratory information system or other data management system should support this traceability.

Ongoing Performance Monitoring Records

After initial validation, the laboratory should maintain records of ongoing assay performance. This includes internal quality control results, external quality assessment results, and any investigations of assay failures or unexpected results. These records provide evidence that the assay continues to perform as validated and support the ongoing verification of assay performance required by ISO 15189.

The ongoing performance records should be reviewed periodically to identify trends or changes in assay performance. Any significant change should trigger investigation and, if necessary, revalidation of the affected parameters. The review of ongoing performance data should be documented, and the conclusions should be recorded.

Common Failure Patterns in Diagnostic Assay Validation

Insufficient Characterization of the Measuring Interval

A common failure in assay validation is inadequate characterization of the measuring interval. The measuring interval, also called the reportable range, is the range of analyte concentrations over which the assay provides reliable results. Validation studies that focus only on the analytical measuring range may miss issues at the extremes of the range, where linearity may be compromised or precision may deteriorate.

The measuring interval should be established using samples with known analyte concentrations spanning the full range of clinical interest. The lower limit of quantification should be distinguished from the limit of detection, and the upper limit of quantification should be established with attention to the hook effect in immunoassays or the saturation of detection systems in molecular assays.

Inadequate Sample Size for Statistical Confidence

Validation studies with insufficient sample sizes may fail to detect performance problems or may produce imprecise estimates of performance characteristics. The number of replicates and the number of runs should be sufficient to provide statistical confidence in the validation conclusions. The CLSI protocols provide guidance on the number of replicates and runs for each type of validation study.

The sample size should also be sufficient to detect clinically meaningful differences from the acceptance criteria. A validation study with too few samples may produce a precision estimate with wide confidence intervals, making it difficult to determine whether the assay meets the acceptance criteria. The validation plan should include a statistical justification for the sample size.

Failure to Use Clinically Relevant Matrices

Validation studies that use idealized matrices, such as buffer solutions or purified analyte, may not reflect the performance of the assay with clinical samples. Matrix effects can substantially impact assay performance, including the limit of detection, precision, and accuracy. The validation studies should use the intended specimen type and should include samples with the range of matrix conditions expected in clinical use.

For assays that use extraction or purification steps, the validation should include the full workflow from specimen processing through final measurement. Validation of only the detection step may miss issues with extraction efficiency, inhibition, or other matrix related effects.

Incomplete Interference and Cross Reactivity Testing

Interference and cross reactivity testing that is not comprehensive may miss clinically significant effects. The selection of interferents and cross reactants should be based on the assay chemistry, the intended patient population, and the differential diagnosis considerations. The validation plan should justify the selection of each interferent and cross reactant.

Interference testing should include both endogenous substances, such as hemoglobin, bilirubin, and lipids, and exogenous substances, such as therapeutic drugs that may be present in patient samples. Cross reactivity testing should include organisms or substances that are phylogenetically related to the target or that may be present in the same clinical specimen.

Inadequate Documentation of Validation Decisions

Validation documentation that does not capture the rationale for key decisions may be difficult to defend during regulatory review or accreditation inspection. The validation report should document the rationale for the intended use statement, the selection of validation parameters, the acceptance criteria, and the study designs. The report should also document any deviations from the validation plan and the investigation of those deviations.

The validation documentation should be organized in a manner that is accessible to reviewers. The relationship between the validation master plan, the study protocols, the raw data, and the validation report should be clear. The documentation should also include the qualifications of the personnel who conducted the validation studies and the review and approval of the validation report.

Biosafety and Containment Considerations in Assay Development

Risk Assessment for Biological Materials

Assay development often involves the use of biological materials, including patient specimens, reference organisms, and recombinant nucleic acids. The biosafety risk assessment should consider the hazards associated with these materials and the appropriate containment measures. The risk assessment should be conducted according to the principles described in the Biosafety in Microbiological and Biomedical Laboratories guidance from CDC and NIH.

The risk assessment should consider the infectious potential of the materials, the route of exposure, the concentration of the agent, and the procedures being performed. The assessment should also consider the potential for aerosol generation, the use of sharps, and the volume of material being handled. The containment measures should be appropriate for the risk level, and the laboratory should have the appropriate facilities and equipment for the work being conducted.

Recombinant and Synthetic Nucleic Acid Oversight

Work with recombinant or synthetic nucleic acid molecules is subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. These guidelines establish the oversight requirements for research involving these molecules, including the role of the Institutional Biosafety Committee. Assay developers working with recombinant or synthetic nucleic acids should determine whether their work is subject to the NIH Guidelines and should comply with the applicable requirements.

The NIH Guidelines classify experiments based on the risk associated with the recombinant or synthetic nucleic acid molecules and the host organisms being used. The classification determines the containment level required and the review process. Assay developers should consult the NIH Guidelines and their institutional biosafety officer to determine the applicable requirements.

Laboratory Biosafety Manual and International Standards

The World Health Organization Laboratory Biosafety Manual provides guidance on biosafety practices that are applicable internationally. The manual addresses risk assessment, containment principles, laboratory design, and safe work practices. The manual is particularly relevant for laboratories operating outside the United States or for laboratories that work with materials that may be subject to international shipping regulations.

The biosafety practices for assay development should be integrated into the validation protocols. This includes procedures for handling specimens, disposing of waste, and responding to spills or exposures. The validation team should receive appropriate biosafety training, and the training should be documented.

Quality Control Integration with Assay Validation

Establishing Quality Control Procedures

The validation process should inform the development of quality control procedures for the assay. The quality control strategy should include internal quality control materials, external quality assessment participation, and ongoing monitoring of assay performance. The quality control procedures should be designed to detect changes in assay performance that could affect clinical results.

Internal quality control materials should be selected based on the assay's measuring range and clinical decision points. The quality control materials should be tested at a frequency that is sufficient to detect changes in assay performance, and the quality control results should be reviewed according to established rules. The quality control rules should be designed to detect both random and systematic errors.

External Quality Assessment and Proficiency Testing

Participation in external quality assessment programs provides an independent assessment of assay performance. The external quality assessment samples should be tested in the same manner as patient samples, and the results should be compared to the results from other laboratories using the same or similar methods. The external quality assessment results should be reviewed, and any significant discrepancies should be investigated.

External quality assessment programs may not be available for all assays, particularly for laboratory developed tests that are not widely used. In the absence of an external quality assessment program, the laboratory should consider alternative approaches for independent assessment of assay performance, such as sample exchange with another laboratory or testing of characterized reference materials.

Ongoing Verification and Revalidation Triggers

The laboratory should have procedures for ongoing verification of assay performance and for determining when revalidation is needed. The ongoing verification should include review of quality control data, external quality assessment results, and any complaints or unexpected results. The verification should also include periodic review of the assay's performance characteristics against the validation data.

Revalidation should be triggered by any significant change to the assay, including changes to reagents, instruments, specimen types, or data analysis methods. Revalidation should also be triggered by evidence of changing assay performance, such as trends in quality control data or discrepancies in external quality assessment results. The revalidation should be proportional to the nature and scope of the change, as described in the CLSI H62 guidance for assay modifications.

Interpretation of Validation Data and Clinical Utility

Linking Analytical Performance to Clinical Decisions

The validation data should be interpreted in the context of the assay's clinical utility. Analytical performance characteristics, such as the limit of detection and precision, are meaningful only in relation to the clinical decisions that will be made based on the assay results. The validation report should describe the relationship between analytical performance and clinical decision making.

For qualitative assays, the validation should address the assay's performance at the clinical decision point, which is the concentration or signal level that distinguishes positive from negative results. The validation should include samples near the clinical decision point to assess the reproducibility of classification at this critical concentration.

For quantitative assays, the validation should address the assay's ability to distinguish clinically meaningful differences in analyte concentration. The precision of the assay should be sufficient to support the clinical decisions that will be made based on the results, such as diagnosis, monitoring, or treatment adjustment.

Diagnostic Accuracy and Clinical Validation

Analytical validation establishes that the assay measures what it is intended to measure, but clinical validation establishes that the assay results are meaningful for the intended clinical use. Clinical validation typically involves comparison of assay results to a clinical reference standard, such as a definitive diagnostic procedure or clinical outcome. The clinical validation should include assessment of diagnostic sensitivity, diagnostic specificity, and predictive values.

The TRIPOD statement provides guidance for the transparent reporting of prediction model studies, which is relevant for assays that are used to predict diagnosis or prognosis. The TRIPOD checklist includes items related to the study design, the participants, the predictors, the sample size, and the statistical analysis. Assay developers should consider the TRIPOD guidance when designing and reporting clinical validation studies.

Limitations of Validation Data

The validation report should clearly describe the limitations of the validation data. This includes the limitations of the sample set, the statistical power of the validation studies, and the generalizability of the results. The limitations should be considered when determining the conditions under which the assay can be implemented and the ongoing monitoring that is required.

The validation data may not fully represent the performance of the assay in all patient populations or all clinical settings. The validation report should describe the patient population and clinical setting in which the validation was conducted and should identify any populations or settings for which the validation data may not be representative.

Common Failure Patterns in Ongoing Assay Performance

Drift in Calibration or Reagent Performance

Assays may show gradual changes in performance over time due to drift in calibration, changes in reagent lots, or degradation of reagents. The quality control procedures should be designed to detect these changes before they affect clinical results. The quality control data should be reviewed for trends, and any significant trend should be investigated.

The investigation of drift should include review of calibration records, reagent lot changes, and instrument maintenance records. The investigation should also include testing of characterized samples to assess the current performance of the assay. If the drift is confirmed, the assay may need to be recalibrated, and the affected patient results may need to be reviewed.

Lot to Lot Variability in Reagents

Changes in reagent lots can introduce variability in assay performance. The laboratory should have procedures for evaluating new reagent lots before they are implemented for clinical use. This evaluation should include testing of quality control materials and, when appropriate, characterized patient samples.

The evaluation of new reagent lots should be documented, and the results should be compared to the performance of the previous lot. If the new lot does not meet the acceptance criteria, the lot should not be implemented, and the manufacturer should be notified.

Operator Dependent Variability

Assay performance may vary depending on the operator, particularly for assays that require manual steps or subjective interpretation. The laboratory should have procedures for training and competency assessment of operators. The training should include the assay procedure, the quality control procedures, and the interpretation of results.

The competency assessment should include direct observation of the operator, review of quality control data, and testing of characterized samples. The competency assessment should be conducted at regular intervals and after any significant change to the assay procedure.

Professional Escalation Criteria for Assay Validation Issues

When to Escalate Validation Concerns

Assay developers should have clear criteria for escalating validation concerns to appropriate institutional oversight. Escalation is appropriate when validation studies fail to meet acceptance criteria, when unexpected results are observed, or when there is disagreement about the interpretation of validation data. Escalation is also appropriate when there are concerns about the safety of laboratory personnel or the integrity of the validation process.

The escalation process should be defined in the validation master plan and should identify the individuals or committees that should be notified. The escalation should include a description of the concern, the relevant data, and the recommended next steps. The escalation should be documented, and the outcome of the escalation should be recorded.

Institutional Biosafety and Regulatory Oversight

Assay development involving biological materials or recombinant nucleic acids may be subject to institutional biosafety oversight. The Institutional Biosafety Committee should be notified of work that is subject to the NIH Guidelines, and the committee should review the work according to the applicable requirements. The committee should also be notified of any significant incidents or exposures.

Regulatory oversight may also be required for certain assay development activities. The FDA should be consulted when there are questions about the regulatory requirements for a specific assay. The laboratory should also be aware of state regulatory requirements, which may be more stringent than federal requirements.

Documentation of Escalation and Resolution

The escalation and resolution of validation concerns should be documented in the validation records. The documentation should include the nature of the concern, the individuals involved, the discussions that occurred, and the resolution. The documentation should be retained as part of the validation record and should be available for review during regulatory inspections or accreditation surveys.

The resolution of validation concerns may involve additional validation studies, changes to the assay procedure, or changes to the acceptance criteria. Any changes to the validation plan should be documented and justified, and the final validation report should reflect the resolution of all concerns.

Frequently Asked Questions

What is the difference between validation and verification of a diagnostic assay?

Validation is the process of establishing that a laboratory developed test or modified method performs as intended for its specific use. Verification is the process of confirming that a method previously validated by the manufacturer performs as claimed when implemented in a specific laboratory. Validation requires evaluation of multiple analytical performance characteristics, while verification typically focuses on accuracy and precision.

How do FDA, CLSI, and ISO 15189 requirements differ for assay validation?

The FDA focuses on analytical and clinical validity for regulatory decision making, with expectations detailed in guidance documents for laboratory developed tests. CLSI provides technical protocols for specific validation studies, such as EP05 for precision evaluation. ISO 15189 integrates validation into a broader quality management system and distinguishes between validation for laboratory developed tests and verification for manufacturer validated methods.

What validation parameters are required for a qualitative diagnostic assay?

Qualitative assays require evaluation of the limit of blank, limit of detection, analytical specificity, and precision of classification near the cutoff. The validation should include samples near the clinical decision point to assess the reproducibility of positive and negative classifications. The validation should also address the assay's performance in the intended specimen type and patient population.

How many samples and replicates are needed for a valid precision study?

The number of samples and replicates depends on the assay type and the precision components being evaluated. CLSI EP05 provides a standardized protocol that typically involves testing multiple samples with multiple replicates per run across multiple days. The sample size should be sufficient to provide statistical confidence in the precision estimates and to detect clinically meaningful deviations from the acceptance criteria.

When should a validated assay be revalidated after a modification?

Revalidation is required when a modification has the potential to affect assay performance. The scope of revalidation should be proportional to the nature and scope of the modification. Minor modifications, such as changing a reagent lot from the same manufacturer, may require only limited verification. Major modifications, such as changing the detection chemistry or specimen type, may require full revalidation of multiple parameters.

What is the role of external quality assessment in assay validation?

External quality assessment provides an independent assessment of assay performance through testing of samples with known or peer group established values. Participation in external quality assessment programs is required by ISO 15189 and is expected by the FDA for laboratory developed tests. External quality assessment results should be reviewed, and significant discrepancies should be investigated.

How should interference and cross reactivity testing be designed?

Interference testing should include potentially interfering substances at clinically relevant concentrations, including endogenous substances and therapeutic drugs. Cross reactivity testing should include organisms or substances that are phylogenetically related to the target or that may be present in the same clinical specimen. The selection of interferents and cross reactants should be justified based on the assay chemistry and intended patient population.

What documentation is required for regulatory acceptance of a validated assay?

The validation documentation should include the validation master plan, individual study protocols, raw data, statistical analysis, and the validation report. The documentation should demonstrate that the validation was conducted according to the approved plan, that the data analysis was appropriate, and that the assay meets the pre specified acceptance criteria. The documentation should also include the qualifications of the personnel who conducted the validation and the review and approval of the validation report.

Related Diagnostic Guides

• Immunoassay Method Validation: Regulatory Guidance and Best Practices
• Cell Viability Assays: Choosing the Right Method for Your Experiment
• Nanotechnology in Rapid Viral Diagnostic Tests
• Steps in the Research Process: A Guide for Diagnostic Assay Development
• Method Validation in Clinical Laboratories: A Practical Protocol

References and Further Reading

• Molecular Biology and Laboratory Methods. National Library of Medicine.
• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules. National Institutes of Health.
• Addgene Protocols. Addgene.
• MIQE Guidelines. Clinical Chemistry.
• NIST Laboratory Programs. National Institute of Standards and Technology.
• Laboratory Biosafety Manual. World Health Organization.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines.. Cytometry. Part B, Clinical cytometry, 2025.
• iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.. The Lancet. Oncology, 2017.
• Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.. Annals of internal medicine, 2015.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.